Cantargia: Funding, Investors & Team (Sep 2026)
The company's foundation lies in the initial finding that leukemic stem cells in individuals with chronic myeloid leukemia (CML) exhibit a particular cell-surface receptor that is not present in normal hematopoietic stem cells. Research has also found an increase in this receptor in stem cells from patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). Cantargia is leveraging this receptor, known as the Interleukin-1 receptor accessory protein (IL1RAP), as the focal point for creating a new antibody-driven treatment for leukemia.
Cantargia has raised $27.5M across 2 funding rounds on record, the most recent an undisclosed round of $2.6M announced in Jun 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Cantargia Company Profile and Key Stats
Latest funding round on record: Jun 2025.
Cantargia Funding Rounds
Cantargia raised $24.9M in a Post-IPO Equity announced in Jun 2022.
3 years later, an undisclosed round of $2.6M was announced in Jun 2025.
Cantargia Founders and Leadership Team
Contact details for the Cantargia team: 1 of 1 has an email address on file.
Start 14-day free trial →Cantargia Funding Compared to Other Biotechnology Startups
Cantargia's latest round of $2.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Cantargia in Biotechnology and Lund
Companies Similar to Cantargia
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
Cantargia Funding FAQs
What does Cantargia do?
The company's foundation lies in the initial finding that leukemic stem cells in individuals with chronic myeloid leukemia (CML) exhibit a particular cell-surface receptor that is not present in normal hematopoietic stem cells. Research has also found an increase in this receptor in stem cells from patients with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). Cantargia is leveraging this receptor, known as the Interleukin-1 receptor accessory protein (IL1RAP), as the focal point for creating a new antibody-driven treatment for leukemia.
How much funding has Cantargia raised?
Cantargia has raised $27.5M across 2 rounds on record. The most recent is an undisclosed round of $2.6M announced in Jun 2025.
When did Cantargia last raise funding?
Cantargia's most recent funding round on record is an undisclosed round of $2.6M, announced in Jun 2025.
Who founded Cantargia?
FundedIQ lists Marcus Jaras (Founder) at Cantargia.
Where is Cantargia headquartered?
Cantargia is based in Lund, Skane Lan, Sweden.
How many employees does Cantargia have?
Cantargia is in the 11-50 employee band.
How does Cantargia's funding compare to other Biotechnology startups?
Cantargia's latest round of $2.6M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Cantargia Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Cantargia is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.